An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
InterMune
Age
20–79
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or Female
Idiopathic Pulmonary Fibrosis
20-79 years
Must have participated in the InterMune protocol GIPF-001 study.
Clareo Health | An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
